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Background. Bisphenol A (BPA) is an ubiquitous chemical contaminant that has recently been associated with adverse eﬀects on
human health. There is incomplete understanding of BPA toxicokinetics, and there are no established interventions to eliminate
this compound from the human body. Using 20 study participants, this study was designed to assess the relative concentration of
BPAinthreebodyﬂuids—blood,urine,andsweat—andtodeterminewhetherinducedsweatingmaybeatherapeuticintervention
with potential to facilitate elimination of this compound. Methods. Blood, urine, and sweat were collected from 20 individuals
(10 healthy participants and 10 participants with assorted health problems) and analyzed for various environmental toxicants
including BPA. Results. BPA was found to diﬀering degrees in each of blood, urine, and sweat. In 16 of 20 participants, BPA was
identiﬁed in sweat, even in some individuals with no BPA detected in their serum or urine samples. Conclusions. Biomonitoring
of BPA through blood and/or urine testing may underestimate the total body burden of this potential toxicant. Sweat analysis
should be considered as an additional method for monitoring bioaccumulation of BPA in humans. Induced sweating appears to
be a potential method for elimination of BPA.
1.Introduction
First synthesized in 1891 and with current production esti-
matedat4billionkilograms eachyearglobally[1],bisphenol
A (BPA) is a multipurpose compound that is widely used in
the modern industrial world. BPA was initially investigated
for its potentially therapeutic estrogenic properties in the
1930s; when diethylstilbestrol (DES) was found to be more
p o t e n t ,h o w e v e r ,B P Aw a st e m p o r a r i l yc a s ta s i d e .I t sc o m -
mercial value was reassessed in the 1950s with the introduc-
tion of BPA as a fundamental component in the manu-
facturing of some plastics. As its primary use currently, BPA
is a key monomer in the production of the most common
form of clear and shatter-proof polycarbonate plastic, but it
has also been incorporated into a variety of everyday goods.
Questions regarding the safety and side eﬀects of BPA
began to emerge in the late 1990s when BPA was found to
leech out of plastics and into experimental animal subjects,
resulting in an increased incidence of chromosomal anomal-
ies in oﬀspring [2]. There has since been ongoing discussion
in both scientiﬁc and political spheres about the potential
for harm resulting from human BPA exposure and potential
bioaccumulation. An overview of the literature regarding the
eﬀects of BPA on human health is provided, followed by a
presentation of data from 20 subjects whose blood, urine,
andsweatweretestedforBPA.Resultsanddiscussionregard-
ing BPA bioaccumulation and elimination are presented for
consideration.
2.Background
Currently, BPA is most commonly found as a component in
polycarbonates (∼74% of total BPA produced) and in the
production of epoxy resins (∼20%). As well as being found
in a myriad of products including plastic food and beverage
containers (including baby and water bottles), BPA is also2 Journal of Environmental and Public Health
commonly found in various household appliances, electron-
ics, sports safety equipment, adhesives, cash register receipts,
medical devices, eyeglass lenses, water supply pipes, and
many other products. It is also frequently used as an adjunct
in the production of brominated ﬂame retardants and brake
ﬂuid [1]. Moreover, BPA derivatives, such as bisphenol A-
glycidyl methacrylate and bisphenol A-dimethacrylate, have
recently been incorporated into the dental industry and used
in dental ﬁllings and sealants. The widespread use of this
compound is receiving increasing scrutiny as concerns about
BPA eﬀects on human health have recently emerged.
Themainmechanismbywhichthepopulationisexposed
toBPAisthroughleachingfromplasticproducts.Thisresults
from either the release of unpolymerized monomers or the
slow decay of polymer bonds in polycarbonates leading to
monomer release into proximal foods and liquids. Occupa-
tional exposures are also present where plastics are burned
and manufactured, and thus BPA may be inhaled by workers
[3, 4]. An analysis of Chinese employees in factories where
BPA and epoxy resins are produced, for example, revealed
that over 90% of exposed workers have notable levels of BPA
in their serum and urine [5].
A plethora of recent studies aﬃrms that the majority of
the population (91–99%) does indeed have detectable levels
of BPA, but the level and the toxicological relevance of cur-
rentexposure levels is a subject of intense academic and pub-
lic health debate [6–13]. An extensive review conducted in
2007concludedthatBPAlevelsinhumanbloodand/orurine
are within the range shown to be dangerous in animals
and are therefore likely to be biologically active in hu-
mans [6]. (As will be discussed, however, blood and urine
testing may underestimate the full extent of exposure and
bioaccumulation.) Conversely, an industry-sponsored liter-
ature review from 2008 declared that daily human consump-
tion was far below dangerous levels and is therefore of mini-
mal concern [7].
Sources of BPA ingestion may vary. In infants and chil-
dren, baby and beverage bottles used by most individuals
in the pediatric population provide ongoing daily sources of
BPA[14–22].Leetal.foundthatatroomtemperature,leach-
ingofBPAoccurredintothecontainedﬂuid,whichincreased
55-fold if boiling water was added [14]. Another study found
thatexposurelevelsincreasednotonlywithtemperature,but
also with repeated use of a container [15].
Other common sources of ingestion include foods stored
in food cans, which are lined with BPA epoxy resin ﬁlms to
preventcorrosion[23–28],thermalprintingpapercommon-
ly used in cash register receipts [29–31], and BPA containing
dental composites and sealants [32–34]. Medical equipment
is also raising concerns about BPA levels as a study of new-
borns found that those who regularly spent time in a neo-
natal intensive care unit had signiﬁcantly higher serum
BPA levels than the general population—thought to be
due to exposure to plastics in medical devices [35]. Like-
wise,dialysispatientsappeartohavehigherratesofexposure,
whichmaybeattributabletocirculatingsolventswhichexpe-
dite the leaching of BPA from polycarbonate hemodialysis
equipment [36, 37].
When ingested, unconjugated BPA—the biologically ac-
tiveformofBPA—hashistoricallybeenthoughttoberapidly
conjugated in the liver and then excreted through bile or
urine, with a half life of approximately 5.3 hours [38–40].
This rapid excretion has been the basis of reassuring safety
evaluations and declarations given by some public health
authoritiesworldwide.However,withinmanytissues,partic-
ularlythelungs,liversandkidneysinrats,andtheplacentaof
animals and humans, β-glucuronidase enzyme is present at
detectable concentration. This enzyme is able to deconjugate
BPA and thus release its active form again [41]. This is of
great signiﬁcance, as it is plausible that, in pregnancy, the
conjugated form of BPA will circulate through the placenta,
undergo deconjugation, and cause subsequent fetal exposure
in utero. This may also result in bioaccumulation of some
portion of BPA after exposure. In fact, recent evidence sug-
gests that at low concentrations, while most plasma BPA
(about 95%) is bound to serum proteins, BPA has lipophilic
aﬃnity with a fat: blood coeﬃcient of 3.3 [42]. Furthermore,
BPAappearstohaveadisproportionateaﬃnitytofatincom-
parison to other tissues such as kidney, muscle, and other
sites; “in fat, the accumulation of BPA was about three times
higher than in other tissues” [42]. With evidence of potential
bioaccumulation, BPA has the prospect of exerting ongoing
metabolic eﬀects.
2.1. Potential Implications of BPA Exposure. BPA is thought
to wield its eﬀects through endocrine disruption, epigenetic
modiﬁcation, cytokine release, and oxidative stress. When
ﬁrst discovered, BPA was investigated for its estrogenic
properties, as it is thought to alter the synthesis of estradiol
andtestosteroneandinterferewithreceptorbinding[43,44].
Consequently, exposure to BPA has been linked with a num-
ber of developmental and reproductive pathologies in both
animalmodelsandhumansubjects.Theseincludeabnorma-
lities in reproductive organ function (irregular cycles, mul-
tiple ovarian cysts, reduction in primordial follicles [45–
49]), placental dysfunction [50], increased incidence of mis-
carriage and neonatal mortality [50, 51], precocious puberty
[52], and sexual dysfunction such as erectile dysfunction,
decreased libido, and ejaculation diﬃculties [53–55].
Moreover, interference with the production and signaling of
sex hormones has led to neurological impairment [56–60].
Synapse formation during development is regulated by
estrogen and androgens; however with exposure to BPA,
a recent study found that levels deemed safe by the US
Environment Protection Agency, completely abolish the
response of synapses to estrogen in the prefrontal cortex and
hippocampus [61].
Epigenetic eﬀects of BPA have been associated with an
increased risk of cancer, particularly breast and prostate
malignancies [62–69]. The exposure of breast epithelial cells
to BPA was found to alter gene expression of 170 genes
and increase their vulnerability to other carcinogens [62,
63]. Additionally, there was silencing of lysosomal-associated
membrane protein 3, as occurs in ERα-positive breast cancer
[62]. Similar eﬀects have been seen with respect to prostatic
disease, as exposure to BPA has been repeatedly shown to
modify methylation of implicated genes [64–66].Journal of Environmental and Public Health 3
Low dose BPA exposure at weaning during the perinatal
periodhasalsobeenfoundtoincreaseadipogenesisinfemale
animals [70]. As it is hypothesized that adult body weight
may be programmed during early life, these results are note-
worthy with regards to the childhood obesity pandemic and
the action of endocrine disruptors as determinants of obesity
[70]. BPA exposure appears to have widespread impact as
it has also been linked by various researchers and studies
throughouttheworldwithawholehostofotherhealthprob-
lems, including metabolic syndrome, obesity, non-insulin-
dependent diabetes mellitus, allergies and asthma, ADHD,
autism, cognitive decline, memory impairment, depression,
and anxiety [71–92]. With the rise of sensitivity-related ill-
ness, there is also concern that BPA may be a determinant of
this recently recognized causative mechanism of disease and
source etiology of assorted clinical conditions [93]b ys t i m u -
lating the release of proinﬂammatory adipokines such as
interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-
alpha) from human adipose tissue [71].
As a result of all the emerging attention in the scientiﬁc
literature, various governments have also embarked on re-
search and policy decisions relating to BPA. In 2010, for
example, the Minister of Health for the Canadian Govern-
ment declared the results of a four-year study indicating,
“The Government of Canada is a world leader in chemicals
management. Our science indicated that Bisphenol A may be
harmful to both human health and the environment” [94].
WithemerginginformationofconcernaboutBPA,theCana-
diangovernmentbecametheﬁrsttoprohibitthesaleofBPA-
containing polycarbonate baby bottles. France, Denmark
and several American states have since implemented simi-
lar regulations.
2.2. Limitations of Toxicant Biomonitoring. It is often assum-
ed that after exposure, BPA is rapidly metabolized to a hor-
monally inactive metabolite and eﬃciently excreted in toto
from the body [95–97]. As a result, there has been little con-
cern about bioaccumulation. The question arises, however,
that if the compound is rapidly excreted without any accrual,
why is there increasing evidence that BPA exposure is any-
thing but innocuous and is able to cause potentially serious
problems in animal and human organisms? While some
believe that only unremitting ongoing exposure to BPA gen-
erates risk, concern has been raised that unrecognized bio-
accumulation of some fraction of BPA may occur in some
exposed individuals. How does one monitor to determine if
toxicant compounds bioaccumulate and thus remain within
the human organism?
Throughout the world, blood and urine sampling are the
general modalities used to biomonitor levels of most toxi-
cant compounds including toxic elements, synthetic com-
pounds, petrochemical compounds, biologic toxicants such
as mycotoxins, and xenobiotics sometimes produced as by-
products from processing of parent compounds [98]. There
is increasing evidence, however, that relying on blood and
urine measurements as indicators of bioaccumulation can be
very ﬂawed [99]. Many compounds sequester in tissues and
donotremaininblood;testingofwholebloodorserummay
misstoxicantswhichhaveexitedthebloodcompartmentand
are being stored primarily in tissues such as bone, muscle,
or adipose compartments. Levels of toxicant compounds can
also rapidly ﬂuctuate with changes in immediate status such
as caloric restriction, level of hydration, underlying nutrient
status, thermal changes, or exercise [98, 100].
Reliance on blood or urine testing for assessment of the
body burden of many toxicants may thus be less than relia-
ble clinically or for public health purposes. As a result, at-
tempts to biomonitor toxicant levels by sampling other tis-
suesandbodilyexcretionshavebeenexplored,includinghair
sampling, salivary testing, stool sampling, perspiration test-
ing, breath analysis, provocation testing, and biopsies of
adipose tissue through needle aspiration into fat pads under
theskin.Itisevident,however,thattherearelimitationswith
each of these approaches. Hair samples, for example may
only reﬂectwhathas been in the blood streamfor the last few
weeks,whilestoolsamplesonlyassesswhatisbeingeliminat-
ed though fecal waste—these do not measure the body
burden. As detailed toxicokinetics for many xenobiotic com-
pounds are not fully understood, it is diﬃcult to know which
proportion of parent compounds and their metabolites
accrue within various bodily compartments.
Some researchers have recently commenced doing fat
biopsies as a tool to biomonitor toxicant levels—this tech-
nique involves taking a sample of fat, usually from the ab-
dominal or gluteal area and sending the sample for analysis.
Recent evidence, however, conﬁrms that toxicants sequester
diﬀerently even within speciﬁc compartments such as adi-
pose tissue; one adipose tissue site may display toxicant con-
centrations that are totally diﬀerent than concentrations at
another site [101]. So the toxicant concentration in brain
adipose tissue, for example, may be very diﬀerent than that
found in breast or abdominal wall adipose tissue.
In review, attempts to biomonitor the levels of toxicant
compounds, including BPA, in humans using a single moda-
lity such as blood or urine are inadequate at best. This is a
challenging realization as most population studies on toxi-
cant compounds reported in the scientiﬁc literature as well
as most ongoing biomonitoring research is based on blood
or urine testing.
2.3. Study Objective. BPA exposure is generally assessed by
measuring urine levels of this compound. In this research,
we endeavor to determine the relative concentrations of BPA
in blood, urine, and sweat. By assessing BPA levels in these
three compartments, the possibility of identifying retained
BPA will be explored as well as the potential for induced
perspiration as a means to eradicate this compound.
3. Methods
3.1. Participant Recruitment. 9 males and 11 females with
mean ages 44.5 ± 14.4 years and 45.6 ± 10.3 years, respec-
tively, were recruited to participate in the study after ap-
propriate ethical approval from the Health Research Ethics
Board of the University of Alberta. 10 participants were pa-
tients with various clinical conditions and 10 were otherwise
healthy adults. Participants with health issues were recruited
from the ﬁrst author’s clinical practice by invitation. Each4 Journal of Environmental and Public Health
Table 1: Participant results for BPA in three body compartments: serum, urine, and sweat.
Participant Gender Age Clinical diagnosis Serum conc. Urine conc. Sweat conc. Sweat/urine ratio Technique used for
sweat collection
1M 6 1 Diabetes, obesity,
hypertension 0 4 82 20.5 Exercise
2 F 40 Rheumatoid arthritis 0 22 24 1.1 Steam sauna
3 M 38 Addiction disorder 0 20 22 1.1 Steam sauna
4 F 25 Bipolar disorder 0 40 22 0.6 Steam sauna
5 F 47 Lymphoma 0 10 24 2.4 Steam sauna
6 F 43 Fibromyalgia 0 32 0 n/a Steam sauna
7 F 48 Depression 0 0 16 n/a Steam sauna
8 F 40 Chronic fatigue 0 0 22 n/a Infrared sauna
9F 6 8 Diabetes, fatigue,
obesity 0 0 10 n/a Steam sauna
10 M 49 Chronic pain, cognitive
decline 0 8 10 1.3 Exercise
1 1 M 5 3 H e a l t h y 1 03 22 0 0 . 6 E x e r c i s e
12 M 23 Healthy 0 30 46 1.5 Infrared sauna
13 M 21 Healthy 30 4 10 2.5 Infrared sauna
14 F 47 Healthy 0 8 12 1.5 Infrared sauna
15 M 53 Healthy 0 4 35 8.8 Infrared sauna
16 F 43 Healthy 0 0 12 n/a Infrared sauna
17 F 51 Healthy 0 0 0 n/a Infrared sauna
18 M 46 Healthy 0 42 0 n/a Infrared sauna
19 M 57 Healthy 0 0 0 n/a Infrared sauna
20 F 50 Healthy 0 8 22 2.8 Infrared sauna
participant in the study provided informed consent and vol-
unteered to give one 200mL random sample of blood, one
sample of ﬁrst morning urine, and one 100mL sample of
sweat. Demographic and clinical characteristics of all re-
search participants are provided in Table 1.
3.2. Samples Collection. All blood samples were collected at
one Dynalife laboratory site in Edmonton, Alberta, Canada
through vacutainer blood collection equipment (BD Vacu-
tainer, Franklin Lakes, NJ, 07417, USA) using 21 gauge stain-
lesssteelneedleswhichwerescrewedintothe“BDVacutainer
One-Use Holder” (REF 364815). The 10mL glass vacutainer
was directly inserted into the holder and into the back end
of the needle. This process and the use of glass were used
to preclude contamination. Blood was collected directly into
plain 10mL glass vacutainer tubes, allowed to clot, and spun
down 30 minutes later. After serum was separated oﬀ,s a m -
ples were picked up by ALS Laboratories (about 3 kilometres
from the blood collection site) for storage pending analysis.
When received at ALS, serum samples were transferred to
4-mL glass vials and stored in a freezer at −20◦C, pending
transfertotheanalyticallaboratory.WechosetoanalyzeBPA
in serum rather than in whole blood, based on the fact that
matrix eﬀect of serum is much lower than whole blood.
For urine collection, participants were instructed to col-
lect a ﬁrst morning urine sample directly into a provided
500mL glass jar container with Teﬂon-lined lid on the same
day that blood samples were collected. Urine samples were
delivered by the participants directly to Edmonton ALS Lab-
oratories. Samples were transferred to 4-mL glass vials and
stored in a freezer at −20◦C, pending transfer.
For sweat collection, participants were instructed to col-
lect perspiration from any site on their body directly into
the provided 500mL glass jar container with Teﬂon-lined
lid—by placing the jar against their prewashed skin when ac-
tively sweating or by using a stainless steel spatula against
their skin to transfer perspiration directly into the glass jar.
(Stainless steel—made up primarily of iron, chromium, and
nickel—was chosen as it is the same material as the needles
used in standard blood collections and is reported not to oﬀ-
gas or leach at room or body temperature.) Excess of 100mL
of sweat was provided in all but one case. Each of the glass
bottles used for sampling in this study was provided by ALS
laboratories and had undergone extensive cleaning and rins-
ing. The containers were deemed appropriate for sweat
collection with negligible risk of contamination: laboratory-
grade phosphate-free detergent wash; acid rinse; multiple
hot and cold deionized water rinses; oven-dried; capping
and packing in quality controlled conditions. Sweat was col-
lected within 1 week before or after doing the blood work.
No speciﬁcations were given as to how long sweating had
commencedbeforecollection.10participantscollectedsweatJournal of Environmental and Public Health 5
Table 2: Comparison of urine BPA levels across published studies.




(ng/mL) Participants Detection(%) AM/GM/Median Range
This study Canada LC-MS 0.2 20 adults 70 AM:13 Median 8 0–42
Bushnik et al. [10] Canada GC-MS 0.2 5462 (age 6–79) 90.7 GM 1.16
(1.08–1.24) N/A
Calafat et al. [9] USA LC-MS 0.4 950 adults N/A GM 2.4 N/A
Calafat et al. [8] USA GC-MS 0.1 394 adults 95 GM 1.33 Median
1.28 0.1–5.18 (95th Centile)
Moors et al. [108] Germany GC-MS 3 15 adults 60 ND-55
Mendiola et al. [107] USA LC-MS 0.4 375 males 90 GM 1.50 <0.4–6.5 (95th Centile)
DL: detection limit; AM: arithmetic mean; GM: geometric mean; ND: non detect; N/A: not available.
LC-MS: liquid chromatography-mass spectrometry.
GC-MS: gas chromatography-mass spectrometry.
inside an infrared sauna; 7 collected inside a regular steam
sauna, and 3 collected during and immediately after exer-
cise—no speciﬁc instruction was given regarding the type or
location of exercise. Sweat was delivered by the participants
directly to ALS laboratories. Samples were transferred to
4mL glass vials and stored in a freezer at −20◦C, pending
analysis. No preservatives were used in the jars provided for
sweat and urine collection, nor in the serum storage vials.
3.3. Analytical Methods. Human serum was analyzed for
levels of bisphenol A (BPA) at ALS Canada following the
generalprocedurespresentedbytheCentresforDiseaseCon-
trol and Prevention [8, 102]. Brieﬂy, samples were fortiﬁed
with 12.5 nanograms of isotopically labelled phthalate meta-
bolites, 50 nanograms of labeled bisphenol-A, 250 nano-
grams of 4-methylumbelliferone glucuronide, 300 micro-
liters of ammonium acetate buﬀer (pH 6.5), and 10 micro-
liters of β-glucuronidase (Escherichia coli K12, Roche Bio-
medical). The samples were mixed and incubated at 37◦C
overnight to allow for the deglucuronidation.
Following enzymatic hydrolysis, a 20uL aliquot of the
sample is added to 70uL of HPLC-grade water and 10ng
of labelled 4-methylumbelliferone to determine deglucuro-
nidation eﬃciency (done once every 100 samples). The re-
maining sample is loaded onto a Zymark Rapid Trace Sta-
tion for automated solid phase extraction (SPE). The 60 mil-
ligram/3mL Oasis-HLB cartridges were conditioned with
HPLC-grademethanol(2mL)and0.1Mformicacid(2mL).
Thesamplesweredilutedwith5mLof0.1Mformicacidand
loaded onto the SPE cartridge at a rate of 1.0mL/min. The
cartridge was washed with water (1mL) and 10% methanol
in water (2mL) at a ﬂow rate of 1mL/min. The samples
were eluted with 1.0mL of acetonitrile at a ﬂow rate of
0.5mL/min. The eluate was evaporated to dryness under a
stream of dry nitrogen and the residue was resuspended in
85% methanol in water (200 microliters) and transferred to
glass autosampler vials.
Quality control of the analysis was maintained by ana-
lysing a method blank (calf serum) and two spiked calf




using an API 4000 liquid chromatograph/tandem mass spec-
trometer.
4. Results and Discussion
Demographic characteristics as well as results for each indi-
vidual participant are summarized in Table 1.A l lc o n c e n t r a -
tions are in nanograms per milliliter.
The fact that some subjects showed undetectable levels
conﬁrms that generalized contamination of these samples is
not likely. Furthermore, the levels of BPA were similar to
those recently published in studies from Italy and Greece
[103] and are comparable with the serum levels found (0.79–
7.12ng/mL) in a recent study by Cobellis et al. in 2009 [104].
The rather low percentage detection among the serum sam-
ples in North America is hard to compare as (to our know-
ledge)thereisonlyonestudyintheliteraturethatdocuments
B P Al e v e l si nb l o o do fN o r t hA m e r i c a n s[ 105]. In that study,
using the same extraction method as the methodology used
in this study, the authors reported BPA levels in the range
of <0.5 (detection limit) to 22.3ng/mL in the blood plasma
of 40 pregnant American women in the state of Michigan.
However, the authors did not report in how many of these
40 women that BPA was detected above their current limit of
detection of 0.5ng/mL. In general, there is major variability
in the range of concentrations of BPA detected in blood, and
this may be explained by the fact that detection methods
vary widely and the speciﬁc populations studied also vary
considerably [106].
For the urine samples, the percentage detection in the
current study (70%) is lower than that of the large scale
Canadian biomonitoring study (90.7%) also known as the
Canadian Health Measures Survey as reported by Bushnik
et al. [10]. However, the geometric mean level of urine BPA
in this study is generally higher than those in other bio-
monitoring studies in North America. Comparative levels
for urine BPA as found in the literature are presented in











compartments. Each cell represents number of study participants.
meanof1.15ng/mLurineBPAinCanadaforasamplesizeof
5462 [10], Calafat et al. found a value of 2.4ng/mL for urine
BPA among 950 American adults aged between 20 and 59 [9]
and more recently Mendolia et al. reported on 375 American
males with a geometric mean value of 1.50ng/mL of urine
BPA [107]. As far as sweat data is concerned, comparison
across studies is impossible as to our knowledge this is the
ﬁrst study which attempts to quantify BPA in sweat.
One obvious qualitative interpretation of the data
from the cohort of 20 study participants is that BPA is
rarely detected in blood, and this is probably why most
large scale biomonitoring studies, such as the NHANES
(National Health and Nutrition Examination Survey) and
CHMS (Canadian Health Measures Survey), use urine as
the human sample of choice to determine exposure levels
in populations. In an attempt to summarize the ﬁndings on
the distribution of BPA in the 3 diﬀerent body ﬂuids, we
give three 2 × 2 tables in Figure 1. As discussed earlier, the 2
discordant pairs urine+/serum− and sweat+/serum−,w i t h
12 and 14 in their respective grids show clearly that serum is
not the appropriate body ﬂuid to test if BPA biomonitoring
in humans is to be characterised. Although there seems to
be high correlation between urine and sweat in terms of
the presence/absence of BPA in these media, with 12 indi-
viduals in the urine+/sweat+ concordant pair, what is more
surprising is that there are 4 individuals for which BPA was
detected in sweat but undetectable in urine (Figure 1C).
In an attempt to compare the excretion eﬃciencies of
urine and sweat for BPA, we calculated the ratio of BPA
concentration in sweat versus urine for those 12 individuals
who are in the urine+/sweat+ concordant pair. As shown
in Table 1, with the exception of 2 individuals (participants
4 and 11) where urine concentration of BPA is slightly
higher than in sweat, in general the ratio is higher than 1,
suggesting that induced sweating may be an eﬃcient method
for eliminating BPA from the body. This is not surprising in
the light of the ﬁndings of Csan´ ady et al. whereby they found
a preferential partitioning of BPA in adipose tissue compared
tobloodwitharatioof3.3[42].ThissuggeststhattheBPAin
bloodwhichisthenconjugatedandexcretedintheurinemay
only represent about one-third of the body burden of BPA. It
is not surprising therefore that induced sweating in saunas
can mobilise BPA in adipose tissue thus leading to enhanced
excretion in sweat. Given that BPA in body fat is mostly
unconjugated,furtherstudieslooking attheratio offreeBPA
to conjugated BPA in sweat will help to conﬁrm whether
the BPA excreted in sweat comes from adipose tissue. Given
that in normal circumstances the daily volume of urine is
much higher than sweat, urine remains an important mode
of elimination of BPA from the human body.
An important consideration in response to the results is
why there are two participants with evidence of BPA in their
urine with no positive level in their sweat. Presumably, the
sweat level may be reﬂective of accrued toxicants in tissue,
whereas urine may reﬂect in part at least recent exposure
which the body is endeavoring to eliminate. It may be
that BPA begins to bioaccumulate only after a threshold of
exposure is reached or once the detoxiﬁcation mechanisms
of the organism are unable to completely eliminate the
BPA load that presents after exposure. Further research is
required in order to clarify, but this result may indicate that
the two individuals have had some recent exposure, but no
signiﬁcant level of stockpiled toxicant. Similarly, the marked
variationintherangeofthesweat/urineratiomayonceagain
be reﬂective of diﬀerent phenomenon: the sweat results may
represent transcutaneous excretion of accured BPA toxicant,
while the urine results are perhaps reﬂecting recent BPA
exposure in addition to some release of accrued BPA that
the body is able to eliminate through renal mechanisms. It
is also noteworthy that there was no statistically signiﬁcant
diﬀerence (P-value >0.05) in sweat BPA levels depending on
the method of sweat collection whether through exercise,
infrared sauna, or regular sauna.
Although this study sheds light on the importance of
sweat as a pathway of elimination for BPA from the body,
it has some limitations. First, given the small study size (n =
20) it is not possible to extrapolate the ﬁndings to the general
population. Secondly, samples were analysed for total BPA,
instead of unconjugated BPA and conjugated BPA separately.
Thirdly, other rare forms of BPA such as chlorinated and
sulfated BPA were not analysed for.
5. Conclusion
As a result of increased scrutiny of health sequelae associated
withhumanBPAexposure,itisapparentthatthisendocrine-
disrupting compound has potentially negative consequences
for the human organism. With new evidence for the
possibility of BPA accrual within the body, interventions to
facilitate elimination of this toxic compound have clinical
relevance with regards to the prevention and treatment of
adverseoutcomesassociatedwithBPAbioaccumulation.The
results of this study suggest that: (i) Sweat testing may be
an additional tool for BPA bio-monitoring; and (ii) Induced
sweating appears to be a clinically useful tool to facilitate the
release of BPA through the skin in order to eliminate this
toxicant from the human body.Journal of Environmental and Public Health 7
Notable ﬁndings and implications of data from this
study
(i) BPA is excreted in sweat
(ii) Sweat BPA concentrations are consistently much
higher than urine
(iii) Only 2/20 participants had BPA in serum, while
16/20 had BPA in sweat
(iv) The data suggests that BPA likely bioaccumulates
to some degree in humans
(v) The data suggests that BPA retained in tissues
(likely adipose) excretes via sweat
(vi) The ﬁnding in some individuals that little or no
B P Ai se x c r e t e di nu r i n ew h i l ec o n s i d e r a b l el e v e l sa r e
found in sweat suggests that current biomonitoring via
serum (as done in Europe) or urine (as done in North
America) may not provide a reliable indication of the
BPA toxicant burden
(vii) With the recognition that BPA has the potential
for hormonal dysregulation, the signiﬁcance of
accrued BPA remains to be conclusively elucidated
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